pargyline has been researched along with oxepins in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andringa, G; Cools, AR; Hafmans, TG; Stoof, JC; Unger, W; van Oosten, RV; Veening, J | 1 |
| Andringa, G; Cools, AR | 1 |
| Jenner, P | 1 |
1 review(s) available for pargyline and oxepins
| Article | Year |
|---|---|
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Topics: Amphetamines; Animals; Antiparkinson Agents; Apoptosis; Clinical Trials as Topic; Drug Evaluation, Preclinical; Haplorhini; Humans; Inactivation, Metabolic; Indans; Mice; Mice, Transgenic; Models, Neurological; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Oxepins; Oxidative Stress; Pargyline; Parkinson Disease; Propylamines; Selegiline | 2004 |
2 other study(ies) available for pargyline and oxepins
| Article | Year |
|---|---|
Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.
Topics: Animals; Antibodies; Apoptosis; Behavior, Animal; Body Weight; Denervation; Dopamine; Exploratory Behavior; Gait; Male; Maze Learning; Nerve Degeneration; Neurons; Oxepins; Oxidopamine; Pargyline; Parkinson Disease, Secondary; Propylamines; Rats; Rats, Wistar; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2000 |
The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey.
Topics: Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Macaca mulatta; Male; Neurons; Neuroprotective Agents; Oxepins; Pargyline; Parkinsonian Disorders; Propylamines | 2000 |